SynthesisFrontiers in oncology2026

PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis.

Juntao Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.